Fate Therapeutics, Inc. FATE
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +112.24%
- 1 year
- +61.24%
- Open
- 2.13
- Prev close
- 2.17
- Mkt cap
- 249.23M
- Vol
- 1.06M
- Avg vol
- 1.58M
- EPS
- -1.05
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.01
- High
- 2.16
- Forward P/E
- -0.99
- Beta
- 1.88
- Short ratio
- 3.10
- Inst. own
- 102.25%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.53
- 200-d avg
- 3.93
- 1y target
- 6.31
5D chart
Signals (57)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 4:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 12:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 4:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 10:45 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:55 AM | 6 days ago |
| SMA: Bearish | Oct 26, 9:55 AM | 6 days ago |
| MACD: Sell Signal | Oct 26, 9:55 AM | 6 days ago |
| MACD: Buy Signal | Oct 26, 9:40 AM | 6 days ago |
| SMA: Bullish | Oct 26, 9:35 AM | 6 days ago |
| SMA: Bullish | Oct 26, 9:35 AM | 6 days ago |
| MACD: Sell Signal | Oct 23, 4:00 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 3:40 PM | 1 week ago |
| SMA: Bullish | Oct 23, 2:45 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:40 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 2:20 PM | 1 week ago |
| RSI: Overbought | Oct 23, 1:55 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:20 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 1:20 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 1:15 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:30 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 12:30 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 12:25 PM | 1 week ago |
News
-
5 days ago benzinga.com
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target
Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.
-
6 days ago benzinga.com
Fate Therapeutics Presents Updated Phase 1 Clinical Data For FT819, Off-The-Shelf, Available On-Demand, Anti-CD19 CAR T-Cell Product Candidate, In Patients With SLE With Lupus Nephritis At ASN Kidney Week 2026
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with…
6 days ago globenewswire.com
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with…
1 month ago globenewswire.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent…
1 month ago globenewswire.com
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent…
1 month ago defenseworld.net
CIRM backs Fate’s FT819 lupus trial
What happened Fate Therapeutics, Inc. (NASDAQ: FATE) said the California Institute for Regenerative Medicine awarded it a $15.0 million CLIN2 grant on September 25, 2026. The grant supports…
-
1 month ago benzinga.com
Fate Therapeutics Receives $15M CIRM Grant To Advance Phase 2 FT819 Trial In Lupus Nephritis
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus NephritisCLIN2 Grant is a highly competitive…
1 month ago globenewswire.com
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis
-
1 month ago benzinga.com
Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentation At ACR Convergence 2026
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
1 month ago globenewswire.com
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent…
-
1 month ago benzinga.com
Fate Therapeutics To Present Clinical Data From Off-The-Shelf Anti-CD19 CAR T-Cell Product Candidate FT819, And Pre-Clinical Data From Anti-CD19 And CD38 CAR T-Cell Product Candidate FT839 At CCR – West Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
1 month ago globenewswire.com
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent…
1 month ago globenewswire.com
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent…
1 month ago defenseworld.net
BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE
BlackRock Inc. acquired a new position in shares of Fate Therapeutics, Inc. (NASDAQ: FATE) in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor…
1 month ago seekingalpha.com
Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead
Fate Therapeutics has initiated the phase 2 RECLAIM-LN trial of FT819 in lupus nephritis, dosing the first patient in an outpatient setting. FATE plans to open 20 trial sites by the end of 2026 and…
-
2 months ago benzinga.com
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8
Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $6 to $8.
-
2 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and raises the price target from $2.5 to $3.5.
-
2 months ago benzinga.com
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target
Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.
-
2 months ago benzinga.com
Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Potentially Registrational Clinical Trial Of FT819 In Patients With Refractory Moderate-To-Severe SLE With Lupus Nephritis
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sitesTrial advances FT819 toward a potential accelerated…
2 months ago globenewswire.com
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites
2 months ago zacks.com
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.29 per share a year ago.
-
2 months ago benzinga.com
Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.79 percent increase over losses of…
2 months ago globenewswire.com
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient…
2 months ago youtube.com
FATE UNKNOWN: If CLARITY DIES Democrats KILLED IT, Lummis says
Sen. Cynthia Lummis, R-Wyo., discusses the expected CLARITY Act vote, the budget agenda before recess, Congress' August checklist and the Democratic Party's direction after Tuesday's primaries on…
2 months ago globenewswire.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent…
3 months ago benzinga.com
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
US stock futures mostly higher, Nasdaq up by 100 points. Phoenix Education falls after cutting sales guidance. Other stocks also down in pre-market.
-
3 months ago benzinga.com
CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application For FT839; Enrollment In Phase 1/2 Trial Anticipated In H2 2026
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
3 months ago globenewswire.com
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development
-
3 months ago benzinga.com
Fate Therapeutics To Demonstrate Data On Its CAR T-cell Product Candidate FT819 At International Society For Stem Cell Research 2026 Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
3 months ago globenewswire.com
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent…
4 months ago globenewswire.com
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent…
4 months ago seekingalpha.com
Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive
Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on FT819 for lupus nephritis. I believe FT819 has made good progress since the last time I covered the…
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Buy and maintains $7 price target.
-
5 months ago benzinga.com
Fate Therapeutics Showcases Data Featuring Its CAR T-Cell Programs At European Congress Of Rheumatology
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
5 months ago benzinga.com
Fate Therapeutics To Feature Data From Off-The-Shelf CAR T-Cell Programs At 2026 ASCO And EULAR Annual Meetings
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
5 months ago benzinga.com
Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 18.75 percent increase over losses of…
-
5 months ago benzinga.com
Fate Therapeutics To Present Data For Its Off-The-Shelf CAR T-Cell Programs At American Society Of Gene And Cell Therapy Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
5 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
-
6 months ago benzinga.com
Fate Therapeutics' FT819 Selected By FDA As Participant In Chemistry, Manufacturing And Controls Development And Readiness Pilot Program To Treat Moderate To Severe Systemic Lupus Erythematosus
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
6 months ago benzinga.com
Fate Therapeutics Announces That Data From Its Off-The-Shelf CAR T-Cell Programs FT819, FT839 And FT836 Will Be Featured At The American Society Of Gene And Cell Therapy Annual Meeting, May 11–15
Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus (SLE) arm of its ongoing Phase 1 trial evaluating FT819 in Regimen B, where FT819 is added to…
-
6 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7
HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $5 to $7.
-
6 months ago benzinga.com
Fate Therapeutics To Present Clinical Data From Its FT819 Candidate At Congress Of Clinical Rheumatology In Florida
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
6 months ago benzinga.com
Fate Therapeutics Says Preclinical Data From Next-Gen, Off-The-Shelf CAR T-Cell Product Candidate, FT839, To Be Featured At 2026 AACR Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.
-
2 years ago benzinga.com
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
-
2 years ago benzinga.com
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
-
2 years ago benzinga.com
Earnings Scheduled For February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
-
2 years ago benzinga.com
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 369 companies hit new 52-week lows.